Greenwich LifeSciences (NASDAQ:GLSI) rose on Wednesday after the immunotherapy developer updated on the commercial manufacture of its lead GP2 candidate, which is currently undergoing a late-stage trial called FLAMINGO-01 for breast cancer.
Given that commercial manufacturing data as well